These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27408334)

  • 1. Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.
    Adachi M; Hoshino Y; Izumi Y; Sakai H; Takagi S
    Can J Vet Res; 2016 Jul; 80(3):209-16. PubMed ID: 27408334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical detection of a potential molecular therapeutic target for canine hemangiosarcoma.
    Adachi M; Hoshino Y; Izumi Y; Takagi S
    J Vet Med Sci; 2016 May; 78(4):649-56. PubMed ID: 26685984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines.
    Murai A; Asa SA; Kodama A; Hirata A; Yanai T; Sakai H
    BMC Vet Res; 2012 Jul; 8():128. PubMed ID: 22839755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma.
    Pyuen AA; Meuten T; Rose BJ; Thamm DH
    PLoS One; 2018; 13(7):e0200634. PubMed ID: 30011343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the phosphatidylinositol 3'-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1.
    Sartelet H; Rougemont AL; Fabre M; Castaing M; Duval M; Fetni R; Michiels S; Beaunoyer M; Vassal G
    Hum Pathol; 2011 Nov; 42(11):1727-39. PubMed ID: 21641013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of the Akt/mTOR/4E-BP1 signalling pathway in canine haemangiomas and haemangiosarcomas.
    Murai A; Abou Asa S; Kodama A; Sakai H; Hirata A; Yanai T
    J Comp Pathol; 2012 Nov; 147(4):430-40. PubMed ID: 22789858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
    Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review: The PI3K-AKT-mTOR signal transduction pathway in canine cancer.
    Meuten TK; Dean GA; Thamm DH
    Vet Pathol; 2024 May; 61(3):339-356. PubMed ID: 37905509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the PI3K-AKT-mTOR signaling pathway promotes DEHP-induced Hep3B cell proliferation.
    Chen X; Qin Q; Zhang W; Zhang Y; Zheng H; Liu C; Yang Y; Xiong W; Yuan J
    Food Chem Toxicol; 2013 Sep; 59():325-33. PubMed ID: 23793038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the PI3K-Akt and mTORC1 signaling pathways promotes the elongation of vascular endothelial cells.
    Tsuji-Tamura K; Ogawa M
    J Cell Sci; 2016 Mar; 129(6):1165-78. PubMed ID: 26826185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
    Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
    Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1.
    Liu Y; Fanburg BL
    Am J Respir Cell Mol Biol; 2006 Feb; 34(2):182-91. PubMed ID: 16195541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.
    Carlson A; Alderete KS; Grant MKO; Seelig DM; Sharkey LC; Zordoky BNM
    Vet Comp Oncol; 2018 Jun; 16(2):253-261. PubMed ID: 29235249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
    Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
    Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.